BCM
BPMC

Bourgeon Capital Management’s Blueprint Medicines BPMC Stock Holding History

Bourgeon Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-200
Closed -$19K – 276
2021
Q1 		$19K Hold
200
– – ﹤0.01% 200
2020
Q4 		$22K Sell
200
-300
-60% -$31.6K 0.01% 181
2020
Q3 		$46K Hold
500
– – 0.01% 148
2020
Q2 		$39K Hold
500
– – 0.01% 130
2020
Q1 		$29K Buy
+500
New +$32.2K 0.02% 129

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bourgeon Capital Management's BPMC Position: Q2 2021 in Review

Bourgeon Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 200 shares — an estimated $19K sold.

Bourgeon Capital Management first reported a position in BPMC in Q1 2020 and held it in 5 quarters. The position peaked at $46K in Q3 2020. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

  • Bourgeon Capital Management reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
  • Bourgeon Capital Management sold 200 Blueprint Medicines shares in Q2 2021, an estimated $19K.
  • Bourgeon Capital Management first reported a position in Blueprint Medicines in Q1 2020 and held it in 5 quarters.
  • Bourgeon Capital Management's Blueprint Medicines position peaked at $46K in Q3 2020.
  • 281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on Bourgeon Capital Management's 13F filing for Q2 2021, filed 19 Jul 2021.